Brokerage Investec downgraded Sun Pharma shares by two notches to 'sell' while Choice Equity Broking gave an 'Add' rating ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...